Ptc Therapeutics (PTCT) Cash & Current Investments (2012 - 2026)

Ptc Therapeutics' Cash & Current Investments history runs 15 years deep, the most recent figure standing at $2.2 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 12.06% year-over-year to $2.2 billion; the TTM figure through Jun 2026 stood at $2.2 billion (up 12.06% YoY), while the FY2025 annual figure was $1.9 billion, up 70.69% from the prior year.
• Cash & Current Investments for Q2 2026 stood at $2.2 billion, up from $1.9 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $2.2 billion in Q2 2026, with the low at $286.3 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $949.1 million (2024), against an average of $1.1 billion.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments sank 66.77% in 2022, then jumped 243.73% in 2024.
• Ptc Therapeutics' Cash & Current Investments stood at $410.7 million in 2022, then jumped by 113.47% to $876.7 million in 2023, then rose by 29.99% to $1.1 billion in 2024, then soared by 70.69% to $1.9 billion in 2025, then grew by 14.58% to $2.2 billion in 2026.
• Business Quant data shows PTCT's Cash & Current Investments at $2.2 billion in Q2 2026, $1.9 billion in Q1 2026, and $1.9 billion in Q4 2025.